A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 501–600 of 1,002
Geerts, H., Spiros, Ä., & Roberts, P. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0343-5 · Cited by 35
Kaur, A., Narang, S. S., Kaur, A., Mann, S., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00168 · Cited by 34
Li, H., Wang, F., Guo, X., & Jiang, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.682247 · Cited by 34
“Inhibiting neurotoxicity by reducing amyloid plaque deposition and NFTs has been unsuccessfully attempted (Doody et al., 2013; Ostrowitzki et al., 2017).”
BackgroundArbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Dave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 37
“It has been evaluated by preclinical trials that inhibiting the secretase enzymes can be clinically helpful (Doody et al. 2013).”
BackgroundPredicting clinical progression trajectories of early Alzheimer's disease patients
Devanarayan, V., Ye, Y., Charil, A., Andreozzi, E. M., Sachdev, P., Llano, D. A., Tian, L., Zhu, L., Hampel, H. J., Kramer, L. D., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13565 · Cited by 35
Liu, L., Lauro, B. M., Li, D., Rovere, M., Wolfe, M. S., & Selkoe, D. J. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.3918 · Cited by 35
“In light of the reported clinical failures of semagacestat [31], a g-secretase inhibitor, and verubecestat [21], a b-secretase inhibitor, inhibition of the secretases for prolonged treatment of AD will be highly challenging.”
BackgroundMolecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 35
Dehury, B., Tang, N., Mehra, R., Blundell, T. L., & Kepp, K. P. (2020) · RSC Advances · doi:10.1039/d0ra04683c · Cited by 34
West Nile Virus-Induced Neurologic Sequelae—Relationship to Neurodegenerative Cascades and Dementias
Vittor, A. Y., Long, M. T., Chakrabarty, P., Aycock, L., Kollu, V., & DeKosky, S. T. (2020) · Current Tropical Medicine Reports · doi:10.1007/s40475-020-00200-7 · Cited by 36
Hu, J., Lin, S. L., & Schachner, M. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04348-6 · Cited by 34
Structure and mechanism of the γ-secretase intramembrane protease complex
Wolfe, M. S., & Miao, Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102373 · Cited by 32
Yan, H., Feng, L., & Li, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s380612 · Cited by 35
Bouillez, A., Gnemmi, V., Gaudelot, K., Hémon, B., Ringot-Destrez, B., Pottier, N., Glowacki, F., Butruille, C., Cauffiez, C., Hamdane, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1768 · Cited by 32
Wilhelmus, M. M. M., de Jager, M., Bakker, E. N. T. P., & Drukarch, B. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132492 · Cited by 33
Emerging roles of the γ-secretase-notch axis in inflammation
Cheng, Y., Choi, Y., Sobey, C. G., Arumugam, T. V., & Jo, D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.005 · Cited by 33
Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets?
Mentrup, T., Loock, A.-C., Fluhrer, R., & Schröder, B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.007 · Cited by 39
Cheng, B., Li, Y., Ma, L., Wang, Z., Petersen, R. B., Zheng, L., Chen, Y., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.013 · Cited by 33
The critical role of γ-secretase and its inhibitors in cancer and cancer therapeutics
Song, C., Zhang, J., Xu, C., Gao, M., Li, N., & Geng, Q. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87334 · Cited by 32
“This is well illustrated by the adverse reactions of Semagacestat (a broad-spectrum GSI), in the Phase III clinical trial of AD [82].”
BackgroundGong, B., Zhang, W., Cong, W., Gu, Y., Ji, W., Yin, T., Zhou, H., Hu, H., Zhuang, J., Luo, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400149 · Cited by 44
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 38
Role of Presenilin in Mitochondrial Oxidative Stress and Neurodegeneration in Caenorhabditis elegans
Sarasija, S., & Norman, K. R. (2018) · Antioxidants · doi:10.3390/antiox7090111 · Cited by 34
Schwartz, M., Ramos, J. M. P., & Ben-Yehuda, H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900844 · Cited by 34
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Advances in Modeling Alzheimer's Disease In Vitro
Sharma, N. S., Karan, A., Lee, D.-H., Yan, Z., & Xie, J. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100097 · Cited by 34
APP Overexpression Causes Aβ-Independent Neuronal Death through Intrinsic Apoptosis Pathway
Cheng, N., Jiao, S., Gumaste, A., Bai, L., & Belluscio, L. (2016) · eNeuro · doi:10.1523/eneuro.0150-16.2016 · Cited by 31
“…through antibody-based clearance of A (Doody et al., 2014; Salloway et al., 2014) or supressing A production by interfering with BACE1 or -secretase activity (Green et al., 2009; Ghosh et al., 2012; Doody et al., 2013), has generally proven ineffective (Karran et al., 2011; Cummings et al., 2014).”
BackgroundFan, F. (2017) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2017.02.555587 · Cited by 32
“However, current treatments and clinical trials targeting these pathways, such as using inhibitors of acetylcholinesterase [15], and γ secretase [16-19] or immunotherapy targeting to Aβ and Tau [18], have not been proved to be able to stop or slow down the disease process of AD.”
BackgroundSemagacestat for Treatment of Alzheimer's Disease
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1310845 · Cited by 30
Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy
Almohmadi, N. H., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103639 · Cited by 30
“50 The negative and undesirable effects of anti-A ß immunotherapies highlight that depletion of A ß in the brain is linked with the development of cognitive impairment due to synaptic failure and dysfunction 47,50 (Table 2).”
The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease
Yu, H.-J., & Koh, S. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.18 · Cited by 35
Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 32
“While there have been a number of high profile clinical failures in this domain (Doody et al., 2013; Selkoe, 2019), there remains significant interest in understanding the mechanisms and pathways leading to protein aggregation, which represents a shared pathogenic pathway in many neurodegenerative conditions.”
BackgroundAmyloid Beta Secreted during Consolidation Prevents Memory Malleability
Finnie, P. S. B., & Nader, K. (2020) · Current Biology · doi:10.1016/j.cub.2020.02.083 · Cited by 32
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 29
“However, multiple previous drug candidates that successfully cleared β -amyloid were abandoned prematurely due to adverse effects, lack of efficacy in cognitive tests, or both (Doody et al., 2013; Egan et al., 2018; Honig et al., 2018).”
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
“Two large multicenter trials enrolling more than 2,000 patients have been conducted (71).”
BackgroundInfluentialHan, M., Lee, E.-H., & Koh, S. (2016) · International Neurourology Journal · doi:10.5213/inj.1632776.388 · Cited by 33
Rockwood, K., Howlett, S. E., Hoffman, D., Schindler, R., & Mitnitski, A. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.005 · Cited by 29
Watari, H., Shimada, Y., Matsui, M., & Tohda, C. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/4086749 · Cited by 29
“Many related clinical trials have been performed worldwide; in spite of numerous efforts, all approaches to improving AD prognoses such as monoclonal antibodies that bind to amyloid beta (Aβ) [4], β-secretase [5], and gamma (γ)-secretase [6] inhibitors have been unsuccessful.”
BackgroundAlginate-Derived Mannuronate Oligosaccharide Attenuates Tauopathy through Enhancing Autophagy
Bi, D., Xiao, S., Lin, Z., Yao, L., Fang, W., Wu, Y. L., Xu, H. Y., Lu, J., & Xu, X. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c00394 · Cited by 29
Dasriya, V. L., Samtiya, M., Dhewa, T., Puniya, M., Kumar, S., Ranveer, S. A., Chaudhary, V., Vij, S., Behare, P. V., Singh, N., et al. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.14043 · Cited by 30
Shared pathophysiology: Understanding stroke and Alzheimer’s disease
Sriram, S., Mehkri, Y., Quintin, S. S., & Lucke-Wold, B. P. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107306 · Cited by 29
Expanding the scope of health disparities research in Alzheimer's disease and related dementias
Akushevich, I. V., Kravchenko, J. S., Yashkin, A. P., Doraiswamy, P. M., Hill, C. V., & Alzheimer's Disease and Related Dementia Health Disparities Collaborative Group (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12415 · Cited by 30
The γ-secretase substrate proteome and its role in cell signaling regulation
Hou, P., Zielonka, M., Serneels, L., Martínez‐Muriana, A., Fattorelli, N., Wolfs, L., Poovathingal, S. K., T’Syen, D., Balusu, S., Theys, T., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.029 · Cited by 31
Grill, J. D., Raman, R., Ernstrom, K. B., Aisen, P. S. S., Dowsett, S. A., Chen, Y.-F., Liu‐Seifert, H., Hake, A. M., Miller, D. S., Doody, R. S., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0122-5 · Cited by 32
“these trials have been reported elsewhere [14,15].”
Self-citationJagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer
Kawaguchi, K., Honda, M., Yamashita, T., Okada, H., Shirasaki, T., Nishikawa, M., Nio, K., Arai, K., Sakai, Y., Yamashita, T., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.04.011 · Cited by 30
Velcicky, J., Bodendorf, U., Rigollier, P., Epple, R., Beisner, D. R., Guerini, D., Smith, P., Liu, B., Feifel, R., Wipfli, P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01371 · Cited by 30
Ong, S. S. Y., Proia, A. D., Whitson, H. E., Farsiu, S., Doraiswamy, P. M., & Lad, E. M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9028-z · Cited by 33
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 29
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 32
“Inhibiting γ-secretase, the other protease required for Aβ production, was tested and abandoned due to on-tar-get toxicity [55, 56].”
Intramembrane proteolysis within lysosomes
Schröder, B., & Säftig, P. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.012 · Cited by 30
Cai, T., Yonaga, M., & Tomita, T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1628-17.2017 · Cited by 28
“However, clinical trials of -secretase inhibitors (GSIs) have been unsuccessful to date, because of their severe adverse effects associated with the inhibition of other -secretase substrates, such as Notch (Doody et al., 2013).”
BackgroundZhao, L., Initiative, A. D. N., Luo, Y., Lew, D., Liu, W., Au, L. W. C., Mok, V., & Shi, L. (2019) · Aging · doi:10.18632/aging.102184 · Cited by 33
Trambauer, J., Fukumori, A., & Steiner, H. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.01.011 · Cited by 31
Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Sun, B., Chen, Y., Fan, D., Zhu, C., Zeng, F., & Wang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1810-y · Cited by 29
Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer’s Disease
Wolfe, M. S. (2021) · Molecules · doi:10.3390/molecules26020388 · Cited by 28
“While there were hopes for a therapeutic window that would allo lo ering brain Aβ levels without the peripheral Notch-deficient toxicity, the failure of o e SI, se agacestat (Fig re 9), in phase III clinical trials, dashed these hopes [72].”
BackgroundIron Responsive Element-Mediated Responses to Iron Dyshomeostasis in Alzheimer’s Disease
Hin, N., Newman, M., Pederson, S., & Lardelli, M. T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210200 · Cited by 29
Molecular basis for isoform-selective inhibition of presenilin-1 by MRK-560
Guo, X., Wang, Y., Zhou, J., Jin, C., Wang, J., Jia, B., Jing, D., Yan, C., Lei, J., Zhou, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33817-5 · Cited by 29
Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Nystuen, K., McNamee, S. M., Akula, M., Holton, K. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11010045 · Cited by 29
Li, S., Hou, H., Mori, T., Sawmiller, D. R., Smith, A., Tian, J., Wang, Y., Giunta, B. N., Sanberg, P. R., Zhang, S., et al. (2015) · Scientific Reports · doi:10.1038/srep11322 · Cited by 29
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
“…pathway, is a substrate of γ‐secretase (Geling, Steiner, Willem, Bally‐Cuif, & Haass, 2002; Micchelli et al., 2003), and blocking Notch cleavage is likely the reason increases in skin cancers and infections were observed in these clinical trials (Chávez‐Gutiérrez et al., 2012; Doody et al., 2013).”
BackgroundVersatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
Kelliny, S., Zhou, X., & Bobrovskaya, L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70046 · Cited by 30
Lenox‐Smith, A., Reed, C. C., Lebrec, J., Belger, M. A., & Jones, R. W. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0748-9 · Cited by 27
Kuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 27
“Semagacestat unfortunately was halted in phase 3 trials due to an association with worsening cognitive function and a predilection for excess skin cancer [105].”
BackgroundZhang, X., Zhong, M., Zhao, P., Zhang, X., Li, Y., Wang, X., Sun, J., Wang, L., Sun, H., Wang, Z., et al. (2019) · Biomaterials Science · doi:10.1039/c9bm00676a · Cited by 29
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 28
Siemers, E., Hitchcock, J., Sundell, K. L., Dean, R. A., Jerecic, J., Cline, E. N., Iverson, K., Moore, J. A., Edgar, C. J., Manber, R., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.93 · Cited by 33
“In addition to reviewing nonclinical data for ACU193, trial designs for other AD treatments including other monoclonal antibodies were evaluated (3, 5, 29-31).”
BackgroundSelf-citationGadiya, Y., Gribbon, P. M., Hofmann‐Apitius, M., & Zaliani, A. (2023) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2023.100069 · Cited by 31
Alzheimer’s Silent Partner: Cerebral Amyloid Angiopathy
Cupino, T. L., & Zabel, M. K. (2013) · Translational Stroke Research · doi:10.1007/s12975-013-0309-7 · Cited by 32
“This is the core of the growing debate surrounding the Amyloid Cascade Hypothesis: Is the place of Aβ aggregation at the origin of AD or a downstream effect from an earlier insult [10]? Additionally, and of considerable concern, multiple recent immunotherapy clinical trials that target and clear Aβ have failed to reve…”
Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
Sogorb‐Esteve, A., García‐Ayllón, M., Llansola, M., Felipo, V., Blennow, K., & Sáez‐Valero, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0705-1 · Cited by 30
“nitively worse in a phase 3 trial [57].”
BackgroundPanayiotou, E., Fella, E., Andreou, S., Papacharalambous, R., Gerasimou, P., Costeas, P., Angeli, S., Kousiappa, I., Papacostas, S., & Kyriakides, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225417 · Cited by 30
γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Alvarez-Trotta, A., Guerrant, W., Astudillo, L., Lahiry, M., Diluvio, G., Shersher, E., Kaneku, H., Robbins, D. J., Orton, D., & Capobianco, A. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3611 · Cited by 26
“Consequently, GSI’s have been clinically hampered by toxicities driven by the essential role of Notch signaling in the intestines, primarily orchestrated by Notch1 and Notch2, and most GSI’s are no longer under clinical development (32-36).”
BackgroundAdvances in Recent Patent and Clinical Trial Drug Development for Alzheimer’s Disease
Liu, H., Wang, L., Su, W., & Xie, X. (2014) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.14.22 · Cited by 26
“It is shown to be orally available, readily cross blood–brain barrier and effectively suppress plasma and brain Aβ level in human APPbearing transgenic mice in a time- and dose-dependent manner with ED50 values of 30 mg/kg in vivo, suggesting its potential for therapy in AD [68]. γ-secretase modulators selectively blo…”
BackgroundInfluentialAmyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 27
Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder
Catania, M., Giaccone, G., Salmona, M., Tagliavini, F., & Fede, G. D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00317 · Cited by 29
“However, when tested in humans, even Notch-sparing GSIs failed to efficiently contrast the disease or their use was early terminated due to unacceptable side effects, especially on liver function (Doody et al., 2013; Pinheiro and Faustino, 2019).”
BackgroundAlzheimer's Disease and Its Potential Alternative Therapeutics.
Kisby, B. R., Jarrell, J. T., Me, A., Ds, C., Er, R., Cm, C., Rogers, J. T., & Huang, X. (2019) · PubMed · doi:10.4172/2161-0460.1000477 · Cited by 27
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 27
Molecular drug targets and therapies for Alzheimer’s disease
Singh, D. B., Gupta, M., Kesharwani, R. K., Sagar, M., Dwivedi, S., & Misra, K. (2014) · Translational Neuroscience · doi:10.2478/s13380-014-0222-x · Cited by 31
Mackey-Alfonso, S. E., Butler, M. J., Taylor, A., Williams-Medina, A. R., Muscat, S. M., Fu, H., & Barrientos, R. M. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.021 · Cited by 26
“…modifying treatments, both of which are controversial and have had varying degrees of success (Wilcock, 2003; Hansen, 2008; Aisen, 2011; Rafii, 2011; Birks and Harvey, 2006; Novak, 2021; van Dyck, 2023; Budd Haeberlein, 2022; Ltd et al., 2014; Wilcock, 2018; Doody, 2013; Herrmann et al., 2011).”
BackgroundWang, Y., Zhu, J., Jia, W., Xiong, H., Qiu, W., Xu, R., & Lin, Y. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c14626 · Cited by 25
Zhao, S., Ye, B., Chi, H., Cheng, C., & Liu, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17454 · Cited by 26
“15 neuroinflammatory responses characterized by the release of inflammatory mediators and cytokines, resulting in neuronal apoptosis, synaptic damage, and glial inflammation [54,55].”
BackgroundImproving the predictive value of interventional animal models data
Zeiss, C. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.015 · Cited by 25
Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives
Wang, J., Tan, L., & Yu, J.-T. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150826 · Cited by 23
Min, K. C., Dockendorf, M. F., Palcza, J. S., Tseng, J., Ma, L., Stone, J. A., Kleijn, H. J., Hodsman, P., Masuo, K., Tanen, M., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1258 · Cited by 26
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 29
Potential immunotherapy for Alzheimer disease and age-related dementia
Schwartz, M., Arad, M., & Ben-Yehuda, H. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/mschwartz · Cited by 30
Delotterie, D. F., Mathis, C., Cassel, J., Dorner‐Ciossek, C., & Marti, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100817 · Cited by 27
Kalium Nitrat (KNO3): Karakteristik Senyawa dan Transpor IonPreprint
Nurfadilah, K. K., & Zainul, R. (2019) · INA-Rxiv (OSF Preprints) · doi:10.31227/osf.io/dr8ef · Cited by 26
Semagacestat's fall: where next for AD therapies?
(2013) · Nature Medicine · doi:10.1038/nm.3365 · Cited by 24
What have we learned from past failures of investigational drugs for Alzheimer’s disease?
Imbimbo, B. P., & Watling, M. I. L. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2017881 · Cited by 26
“There are also data suggesting that these drugs may accelerate brain atrophy in patients [31,32].”
BackgroundProtein structures in Alzheimer's disease: The basis for rationale therapeutic design
Montoliu‐Gaya, L., & Villegas, S. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.10.005 · Cited by 28
Links Between Adiponectin and Dementia: From Risk Factors to Pathophysiology
Chen, R., Shu, Y., & Zeng, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00356 · Cited by 26
Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue
Saretz, S., Basset, G., Useini, L., Laube, M., Pietzsch, J., Drača, D., Maksimović‐Ivanić, D., Trambauer, J., Steiner, H., & Hey‐Hawkins, E. (2021) · Molecules · doi:10.3390/molecules26102843 · Cited by 24
“The side effects are considered to be the result of a mechanism-based toxicity due to the interference with the cleavage of other crucial γ-secretase substrates such as the transmembrane receptor Notch, which is important for nuclear signalling [6].”
BackgroundPeptides Derived from Growth Factors to Treat Alzheimer’s Disease
Gascon, S., Jann, J., Langlois-Blais, C., Plourde, M., Lavoie, C. L., & Faucheux, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116071 · Cited by 25
Eskandari, S., Sajadimajd, S., Alaei, L., Soheilikhah, Z., Derakhshankhah, H., & Bahrami, G. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00381-7 · Cited by 26
Asih, P. R., Chatterjee, P., Verdile, G., Gupta, V. B., Trengove, R. D., & Martins, R. N. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.29 · Cited by 25
Gamma secretase inhibitors: a patent review (2013 - 2015)
Gu, K., Li, Q., Lin, H., Zhu, J., Mo, J., He, S., Lü, X., Jiang, X., & Sun, H. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1313231 · Cited by 23
“This compound was the first to progress into the phase III clinical trial, but the outcome of the clinical trial of Compound 15 was disappointing because the most serious problem is the worsening of memory in patient [60], and the mechanism of cognitive decline is elusive.”
BackgroundYoun, H., & Jeong, H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.12.758 · Cited by 25
DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells
Xiang, J., Zhang, W., Cai, X., Cai, M., Yu, Z., Yang, F., Zhu, W., Li, X.-T., Wu, T., Zhang, J., et al. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.02.025 · Cited by 19
Mounting evidence of FKBP12 implication in neurodegeneration
Caminati, G., & Procacci, P. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.284980 · Cited by 23
“…proline residues, with the potential of being involved in a large number of metabolic pathways and physiological processes, (Schiene et al., 1998; Dunyak and Gestwicki, 2016) including folding of nascent polypeptide chains, transport of proteins (Ghartey-Kwansah et al., 2018), viral replication…”
Background
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.